- BOOK REVIEW: 'Please Stop Helping Us': Black Conservative Deconstructs Unintended Consequences of Affirmative Action, Minimum Wage Laws, Public Schools
- REALTORS: Pending Home Sales Rise 3.3% in July
- Former Mail Carrier Made Over 100 Drug Deals While on Duty
- Huntington Residents Help Police Nail Two More Detroit Drug Suspects
- Chief Johnson Shakes Up Huntington Druggies in a Style Reminiscent of John Wayne
- CARIBBEAN VIEW: Scotland’s Independence: Does it matter?
- Taut "November Man" Debuts; "As Above" Has MU Film Connection
- CARIBBEAN VIEW: No Caribbean Appetite for a Rum Fight
- Appalachian Uprising Becomes Jewel City Jamboree in 2015
- Keith-Albee Performing Arts Center joins National Trust for Historic Preservation
Biomedical sciences researcher to present results of clinical trials on personalized chemotherapy
Thursday, June 12, 2014 - 03:21 Updated 10 weeks ago Special to HNN Provided by Marshall University
He will be discussing the results of clinical trials conducted at the Edwards Comprehensive Cancer Center. The studies tested ChemoID, a cell culture method he developed with colleague Dr. Jagan Valluri to measure the sensitivity of patients' tumors to chemotherapy treatment for lung, brain/spine and breast cancer.
He says more evaluation of the technology is needed, but preliminary tests on a small number of patients found ChemoID 100 percent accurate in predicting which drug is more effective in treating patients affected by brain cancer if the tumor-initiating cancer stem cells were evaluated.
"Oncologists every day face many challenges in determining the best course of therapy for an individual cancer patient," says Claudio. "The basic problem is that patients with similar diagnoses don't always respond to the same chemotherapy. This technology we have developed could help physicians select the appropriate chemotherapy for an individual patient giving them an edge in the fight against cancer."
He says the good news for cancer patients is that ChemoID may make possible personalized treatment by predicting the most effective drug combination to successfully target that specific patient's cancer increasing the chance the drugs will work and perhaps reducing side effects by helping the patient avoid unnecessary drugs.
In addition to presenting his own research at the conference, Claudio will be moderating a session, "Advances in Oncology and Anticancer Research. Cancer Pathology."
Summaries of the research presented at the meeting will be published in the journal Frontiers in Bioscience.